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Summary
Background Understanding the genetic basis of airﬂ ow obstruction and smoking behaviour is key to determining the 
pathophysiology of chronic obstructive pulmonary disease (COPD). We used UK Biobank data to study the genetic 
causes of smoking behaviour and lung health.
Methods We sampled individuals of European ancestry from UK Biobank, from the middle and extremes of the 
forced expiratory volume in 1 s (FEV1) distribution among heavy smokers (mean 35 pack-years) and never smokers. 
We developed a custom array for UK Biobank to provide optimum genome-wide coverage of common and low-
frequency variants, dense coverage of genomic regions already implicated in lung health and disease, and to assay 
rare coding variants relevant to the UK population. We investigated whether there were shared genetic causes 
between diﬀ erent phenotypes deﬁ ned by extremes of FEV1. We also looked for novel variants associated with 
extremes of FEV1 and smoking behaviour and assessed regions of the genome that had already shown evidence for a 
role in lung health and disease. We set genome-wide signiﬁ cance at p<5 × 10–⁸.
Findings UK Biobank participants were recruited from March 15, 2006, to July 7, 2010. Sample selection for the UK 
BiLEVE study started on Nov 22, 2012, and was completed on Dec 20, 2012. We selected 50 008 unique samples: 
10 002 individuals with low FEV1, 10 000 with average FEV1, and 5002 with high FEV1 from each of the heavy smoker 
and never smoker groups. We noted a substantial sharing of genetic causes of low FEV1 between heavy smokers 
and never smokers (p=2·29 × 10–¹⁶) and between individuals with and without doctor-diagnosed asthma 
(p=6·06 × 10–¹¹). We discovered six novel genome-wide signiﬁ cant signals of association with extremes of FEV1, 
including signals at four novel loci (KANSL1, TSEN54, TET2, and RBM19/TBX5) and independent signals at two 
previously reported loci (NPNT and HLA-DQB1/HLA-DQA2). These variants also showed association with COPD, 
including in individuals with no history of smoking. The number of copies of a 150 kb region containing the 5ʹ end 
of KANSL1, a gene that is important for epigenetic gene regulation, was associated with extremes of FEV1. We also 
discovered ﬁ ve new genome-wide signiﬁ cant signals for smoking behaviour, including a variant in NCAM1 
(chromosome 11) and a variant on chromosome 2 (between TEX41 and PABPC1P2) that has a trans eﬀ ect on 
expression of NCAM1 in brain tissue.
Interpretation By sampling from the extremes of the lung function distribution in UK Biobank, we identiﬁ ed 
novel genetic causes of lung function and smoking behaviour. These results provide new insight into the speciﬁ c 
mechanisms underlying airﬂ ow obstruction, COPD, and tobacco addiction, and show substantial shared genetic 
architecture underlying airﬂ ow obstruction across individuals, irrespective of smoking behaviour and other 
airway disease.
Funding Medical Research Council.
Copyright © Wain et al. Open Access article distributed under the terms of CC BY.
Introduction
Chronic obstructive pulmonary disease (COPD) is a 
global public health concern and is currently the third 
leading cause of death worldwide.1 Smoking and indoor 
air pollution are major environmental risk factors for 
development of COPD, but heritability studies also 
suggest a strong genetic component in smoking 
behaviour and in risk of COPD.1–4 Spirometry, particularly 
measurements of forced expiratory volume in 1 s (FEV1) 
and forced vital capacity (FVC), is used to measure 
airﬂ ow obstruction and helps in the diagnosis and 
grading of severity of COPD. Previous large genome-wide 
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association studies (GWAS) of general population 
cohorts have identiﬁ ed 32 common genetic variants 
(minor allele frequency [MAF] >5%) associated with lung 
function,5–9 12 of which have also shown association with 
airﬂ ow obstruction and risk of COPD.10–15 However, these 
ﬁ ndings only explain a small proportion of the phenotypic 
variance (~1·5% for FEV1).8
Tobacco smoking accounted for about 5·1 million deaths 
globally in 2004 and for 18% of deaths in high-income 
countries.16 Large GWAS of smoking behaviour17–19 have 
identiﬁ ed up to eight associated loci; the strongest 
association reported is at the 15q25 locus.17–19 Further insight 
into the genetic factors aﬀ ecting lung function, smoking 
behaviour, and COPD could lead to new approaches for 
smoking cessation and prevention and treatment of COPD.
UK Biobank is the largest European biobank available at 
present and represents an extensive resource from which 
to sample phenotypic extremes in the UK population.20 
UK Biobank contains data from 502 682 individuals 
(94% of self-reported European ancestry), with extensive 
health and lifestyle questionnaire data, physical measures 
(including spirometry), and DNA.
In the UK Biobank Lung Exome Variant Evaluation 
(UK BiLEVE) study, we undertook nested case-control 
studies in individuals of European ancestry from UK 
Biobank to: (1) identify whether there are shared genetic 
causes underlying low FEV1 and high FEV1, and a shared 
genetic cause of low FEV1 between never smokers and 
heavy smokers and between individuals with and without 
a doctor diagnosis of asthma; (2) identify novel variants 
associated with extremes of FEV1 and smoking behaviour; 
and (3) provide further insight into regions of the 
genome that had already shown evidence for a role in 
lung health and disease.
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Research in context
Evidence before this study
UK Biobank had completed its recruitment, including its 
baseline phenotyping and biobanking of samples, before our 
study began. The DNA had not yet been extracted from the 
biobanked samples, and the spirometry data quality had not yet 
been analysed across all UK Biobank participants. We searched 
for evidence of other large biobanks with spirometry data, 
including the P3G Catalogue. We did not identify any other 
biobank with spirometry data and DNA as large as UK Biobank. 
Evidence regarding the global burden of disease due to smoking 
or chronic obstructive pulmonary disease (COPD) was obtained 
from the WHO Global Health Risks Report and a systematic 
analysis of the Global Burden of Disease Study 2010. Tobacco 
smoking accounted for about 5·1 million deaths globally in 
2004; because of recent increases in smoking prevalence in 
developing countries, the full global eﬀ ect of smoking is yet to 
occur. COPD is the third leading cause of death globally. For 
previous evidence of genetic associations, we gave the highest 
ranking to associations reaching genome-wide signiﬁ cance in 
genome-wide association studies, a lower ranking to 
associations not reaching genome-wide signiﬁ cance in 
genome-wide association studies, and the lowest ranking to 
associations reported in candidate gene studies. To assess 
evidence of loci associated with lung function, COPD, and 
smoking behaviour, we queried the Catalog of Published 
Genome-Wide Association Studies. We used this evidence to 
report our known ﬁ ndings for genetic variants shown to be 
associated with forced expiratory volume in 1 s (FEV1; eight loci) 
and smoking behaviour (seven loci). We report candidate gene 
associations only for variants for which we found genome-wide 
evidence of association.
Added value of this study
We describe, to our knowledge, the ﬁ rst genetic study using 
the UK Biobank resource and show the quality of the 
phenotype and genotype data. Additionally, we describe an 
advance in imputation quality aﬀ orded by the use of a newly 
designed genotyping array used in conjunction with the 
largest reference panel available so far. A slightly modiﬁ ed 
version of this array is being used to genotype the remaining 
samples in UK Biobank. As evidence of the usefulness of these 
data, we describe novel insights into the genetic architecture 
of airﬂ ow obstruction and smoking. Speciﬁ cally, we show that 
there are shared genetic causes of airﬂ ow obstruction 
between smokers and non-smokers, consistent with the 
limited evidence for gene–smoking interactions described so 
far. We show that the genetic determinants of low FEV1 in 
individuals without asthma are also informative in individuals 
with asthma. We report new loci associated with extremes of 
FEV1 and COPD, including evidence that a genomic region of 
complex structural variation has an eﬀ ect on lung function 
and airﬂ ow obstruction in the general population. Our novel 
signals implicate epigenetic mechanisms as contributors to 
lung health. These ﬁ ndings, taken together with previous 
ﬁ ndings, will help deﬁ ne pathways underlying predisposition 
to development of COPD and smoking behaviours. A full 
understanding of the biological mechanisms underlying these 
genetic associations will improve our understanding of the 
pathophysiology of COPD and smoking behaviour, and 
potentially give rise to novel therapeutic strategies for the 
management of airway disease and prevention of nicotine 
addiction.
Implications of all the available evidence
This study has improved our understanding of the genetic and 
molecular basis of smoking behaviour and lung function and 
provided potential targets for therapeutic intervention. It has 
also shown the value of sampling from the extremes using a 
large biobank such as UK Biobank. A similar approach could be 
adopted for genetic studies of other health-related traits in UK 
Biobank, using either new genetic assays or the extensive 
genome-wide data that we and UK Biobank have generated. 
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Methods
Study design
We deﬁ ned case and control groups by selecting individuals 
from the middle and extremes of the FEV1 distribution 
among both heavy smokers (mean 35 pack-years) and 
never smokers. We developed a custom array to provide 
optimum genome-wide coverage of common and low 
frequency (MAF 1–5%) coding variants and rare (MAF 
<1%) coding variants relevant to the UK population; this 
platform also provided dense coverage of genomic regions 
implicated in lung health and disease. Spirometry data in 
UK Biobank were obtained using a Vitalograph 
Pneumotrac 6800 (Buckingham, UK) on at least two 
occasions. Sampling was undertaken such that equal 
numbers of males and females were selected in total and 
the numbers of individuals selected from each age–sex 
band were proportional to the number of individuals in the 
band being sampled (appendix pp 3–5). One consequence 
of this approach is that we enriched our sample for non-
smoking individuals with airﬂ ow obstruction. 
To assess whether the novel regions that we identiﬁ ed 
as associated with FEV1 extremes are also associated with 
COPD, we deﬁ ned individuals fulﬁ lling spirometric 
criteria for the Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) Stage 2+ COPD (FEV1:FVC ratio 
<0·7 and percent predicted FEV1<80%) as COPD cases 
and we deﬁ ned individuals with FEV1:FVC ratio >0·7 and 
percent predicted FEV1 in excess of 80% from the high 
FEV1 strata as controls. Post-bronchodilator spirometry 
was not available, although drug treatment was not 
withheld before spirometry.
To assess the extent of the shared genetic causes of low 
FEV1 between individuals with and without reported or 
doctor-diagnosed asthma, we identiﬁ ed individuals with-
in our study selection who were also asthma cases as 
participants who either (1) answered “asthma” to the 
touch-screen question “Has a doctor ever told you that 
you have had any of the following conditions?” or 
(2) reported asthma in a verbal interview at the time of 
recruitment to UK Biobank. 
UK Biobank has received ethics approval from the 
National Health Service National Research Ethics Service 
(Ref 11/NW/0382).
Procedures
We undertook genome-wide genotyping of variants using 
a new custom Aﬀ ymetrix Axiom array (UK BiLEVE array; 
Santa Clara, CA, USA; appendix pp 5–8) that was 
designed to (1) measure rare coding variation; (2) provide 
a framework for optimum imputation of non-genotyped 
variants that are common (MAF >5%) or of low frequency 
(MAF 1–5%) in the European population, when used in 
conjunction with a large imputation reference panel of 
individuals with whole-genome sequence data;21 and 
(3) optimise coverage of genes and genomic regions with 
established or putative roles in lung health and disease to 
enable ﬁ ne mapping. After thorough sample and variant 
quality control (appendix pp 8–15), we imputed non-
genotyped variants using a combined 1000 Genomes 
Project Phase 122 and UK10K Project23,24 reference panel 
(appendix pp 15–16). The data were used to ﬁ nalise the 
design of the UK Biobank array, which is being used for 
genome-wide genotyping and imputation of the 
remaining UK Biobank participants. 
Using data from previously published studies of 
whole-genome gene expression and genome-wide geno-
typing,25–29 we assessed whether variants at associated loci 
(identiﬁ ed as described in the Statistical analysis) 
regulate levels of mRNA. These expression quantitative 
trait loci (eQTL) studies included non-tumour lung 
tissue, blood, and, for variants associated with smoking 
behaviour, brain. For genes close to peaks of novel 
signals or genes implicated through eQTL, we assessed 
diﬀ erential expression in the lungs of individuals with 
and without COPD and diﬀ erential expression in the 
pseudoglandular and canalicular stages of development 
of the fetal lung.30,31 Additionally, we generated RNA 
sequencing data to discover novel transcripts of these 
genes in human bronchial epithelial cells. We tested all 
genome-wide meta-analysis p values for enrichment in 
biological pathways deﬁ ned in publicly available 
databases. All functional analyses are described in detail 
in the appendix (pp 21–23).
Statistical analysis
Case-control comparisons of low FEV1 versus high FEV1, 
low FEV1 versus average FEV1, and high FEV1 versus 
average FEV1 were done within each of the heavy and 
never smokers subsets separately (appendix p 17). To 
identify whether any individual variants had a 
signiﬁ cantly diﬀ erent eﬀ ect on the risk of airﬂ ow 
obstruction in heavy smokers compared with never 
smokers, we tested for interaction with smoking 
(appendix p 17). We calculated the proportion of the 
variance in FEV1 explained by genetic variants (appendix 
p 17). We compared heavy versus never smokers to 
identify loci associated with smoking behaviour. 
Association testing was done using a Score test (and 
Firth test for variants with minor allele count <400)32 with 
imputed marker doses, adjusting for pack-years in 
smokers and ten principal components. Full genome-
wide association results are available via UK Biobank 
(appendix p 17). For genome-wide association analyses, 
we set genome-wide signiﬁ cance as p<5 × 10–⁸ and 
suggestive signiﬁ cance as 5 × 10–⁸<p<5 × 10–⁷. For other 
analyses, we used a Bonferroni correction for multiple 
testing. The appendix (p 17) describes quality control 
after association testing. For the lead single nucleotide 
polymorphism (SNP) at each of our novel signals of 
association with FEV1 extremes, we tested for association 
with COPD risk using the aforementioned deﬁ nition 
(appendix p 18). We did a meta-analysis across smoking 
strata using inverse variance weighting. We assessed 
evidence for polygenic architecture of FEV1-deﬁ ned 
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phenotypes (appendix p 18).33 For this analysis, we created 
discovery and target subpopulations, each of which 
comprised cases and control groups created by randomly 
splitting the low FEV1 and average FEV1 groups (appendix 
pp 18–20). Variants of MAF of at least 1% associated with 
low FEV1 below given p value thresholds in the discovery 
Figure 1: Sample selection strategy
ATS=American Thoracic Society. ERS=European Respiratory Society.34 FEV1=forced expiratory volume in 1 s. FVC= forced vital capacity. *See appendix (pp 3–5) for more 
details of sample selection. 
10 002 samples from
heavy smokers
with low FEV1
10 000 samples from
heavy smokers
with average
FEV1
10 002 samples from
never smokers
with low FEV1
10 000 samples from
never smokers
with average
FEV1
5002 samples from
never smokers
with high FEV1
5002 samples from
heavy smokers
with high FEV1
9748 samples 
 available after 
 quality 
 control
9803 samples 
 available after 
 quality 
 control
4906 samples 
 available after 
 quality 
 control
502 682 individuals in UK Biobank in full sampling frame 
472 858 samples of white European ancestry
275 939 samples with FEV1 and FVC measures meeting 
 ATS/ERS criteria
152 030 samples selected as having heavy or never 
 smoking status
50 008 samples included in analyses 
102 022 samples not selected as 
 having high, low, or 
 average percent predicted 
 FEV1*
426 797 samples with at least two FEV1 and FVC
measures and complete information for
spirometry method, age, sex, and standing height
29 824 samples from individuals not of white European ancestry
46 061 samples with incomplete phenotype data excluded
150 858 samples not meeting ATS/ERS criteria
123 909 samples excluded
123 895 from individuals not classified as never
smokers or heavy smokers, or whose smoking
history could not be established
14 from individuals with extreme FEV1 values
105 272 samples from individuals identified as never smokers 46 758 samples from individuals identified as heavy smokers
9745 samples 
 available after 
 quality 
 control
9827 samples 
 available after 
 quality 
 control
4902 samples 
 available after 
 quality 
 control
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population were incorporated into an aggregate score, 
and the association with the aggregate score was tested 
in the independent target population. A similar approach 
(appendix pp 18–20), in each case using independent 
discovery and target populations, was used to test for a 
shared polygenic component between high FEV1 and low 
FEV1, low FEV1 in heavy smokers and in never smokers, 
and low FEV1 in participants who did and those who did 
not report a history of doctor-diagnosed asthma. To show 
the reliability of the doctor diagnosis of asthma variable, 
we showed association with asthma at ten previously 
reported genome-wide signiﬁ cant loci (appendix 
pp 21, 29). 
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding authors had full access to 
all the data in the UK BiLEVE study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
UK Biobank participants were recruited from March 15, 
2006, to July 7, 2010. Sample selection for the UK BiLEVE 
study started on Nov 22, 2012, and was completed 
on Dec 20, 2012. We initially selected 50 008 unique 
samples representing the extremes and middle of the 
percent predicted FEV1 distributions; this comprised 
10 002 individuals with low percent predicted FEV1, 
10 000 individuals with average percent predicted FEV1, 
and 5002 individuals with high percent predicted FEV1 
from each of the heavy smoker and never smoker groups 
(ﬁ gure 1). Within this dataset, 48 931 unrelated individuals 
passed quality control and were included in subsequent 
analyses.
We undertook genome-wide genotyping of 
807 411 variants. After ﬁ ltering, genome-wide imputation 
using the 1000 Genomes Project Phase 1 and UK10K 
Project reference panel resulted in 42 795 484 variants. 
Our ﬁ nal dataset for analysis, after excluding variants 
with information quality less than 0·5 or minor allele 
count less than three, comprised 28 509 962 imputed or 
genotyped variants in 48 931 unrelated individuals (table 1 
and appendix pp 16 and 95).23
Using independent discovery and target sub populations 
to generate and test risk scores, we found that the 
association of low FEV1 versus average FEV1 with the risk 
score became stronger for increasingly liberal p value 
thresholds of association in the discovery population 
(p=6·24 × 10–¹⁶ for a p value threshold of 0·5). This ﬁ nding 
suggests a polygenic component to low FEV1, in which 
many variants of individually small eﬀ ect size contribute 
to the risk of low FEV1. We found substantial sharing of 
genetic causes across thousands of genetic variants 
between low FEV1 in heavy smokers and low FEV1 in never 
smokers (p=2·29 × 10–¹⁶; p value threshold <0·5; ﬁ gure 2; 
appendix p 30). Similarly, we found substantially 
overlapping genetic causes for low FEV1 in participants 
reporting a history of doctor-diagnosed asthma and low 
FEV1 in those without asthma (p=6·06 × 10–¹¹; p value 
threshold <0·5; ﬁ gure 2; appendix p 31). Finally, 
overlapping genetic causes were shown for high FEV1 and 
low FEV1 (p=1·64 × 10–²²; p value threshold <0·5; ﬁ gure 2; 
appendix p 30).
In addition to detecting signals of association 
previously reported by studies of quantitative lung 
function (appendix p 32–37), in our case-control analysis 
of FEV1 extremes we identiﬁ ed six novel signals of 
association (p<5 × 10–⁸) with low FEV1 versus high FEV1 
(table 2; ﬁ gure 3; appendix pp 38–53, 96–98, 102). The 
sentinel SNPs at ﬁ ve of these six signals, in or near TET2, 
NPNT, HLA-DQB1/HLA-DQA2, KANSL1, and TSEN54, 
were common (MAF ≥5%) and showed a stronger 
association with low FEV1 in never smokers than heavy 
smokers. The sentinel SNP at an intergenic signal 
between RBM19 and TBX5 was a rare variant 
(MAF=0·13%) that showed strongest association with 
low FEV1 in heavy smokers. The lead SNPs at each of 
these loci showed association with COPD (table 2; 
appendix p 55). The 26 previously reported SNPs 
Heavy smokers Never smokers
Number of 
individuals 
(n=24 457)
Absolute 
FEV1 (L)
Predicted FEV1 
(%)
Number of 
individuals 
(n=24 474)
Absolute 
FEV1 (L)
Predicted FEV1 
(%)
Low FEV1 9748 1·93 (0·55) 65·6% (11·8) 9745 2·05 (0·54) 69·3% (10·0)
Average FEV1 9803 2·68 (0·56) 90·6% (3·9) 9827 2·92 (0·57) 98·7% (1·3)
High FEV1 4906 3·49 (0·72) 118·0% (8·1) 4902 3·83 (0·73) 130·3% (8·3)
Data are mean (SD), unless otherwise speciﬁ ed. See appendix (pp 3–5) for details of sample selection. FEV1=forced 
expiratory volume in 1 s. 
Table 1: Absolute and percent predicted forced expiratory volume in 1 s in each subgroup in heavy and 
never smokers 
Figure 2: Polygenic component of low forced expiratory volume in 1 s and shared polygenic component of 
diﬀ erent phenotypes deﬁ ned by forced expiratory volume in 1 s, smoking, and doctor diagnosis of asthma
The p value in the target population shown above the bars is for the p value threshold <0·5. The sample sizes 
diﬀ ered between the comparisons; details of these and the assumptions used in the analyses are described in the 
appendix (pp 18–20). FEV1=forced expiratory volume in 1 s.
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(associated with FEV1, FEV1:FVC ratio, or both)5,7–9 
explained 2·33% of the variance of FEV1 in our data; 
adding in the SNPs representing our six novel signals of 
association with FEV1 extremes, we explained 3·63% of 
the variance of FEV1 (appendix p 17).
Although association with lung function at 4q24 is well 
established,5,7 we report two further independent signals of 
association at this locus (table 2; appendix pp 56–57, 
99–101). The ﬁ rst (rs34712979) was localised to NPNT but 
independent of the previously reported signal, which 
 Locus Non-coded/
coded allele 
(minor allele)
Imputation 
info score*
Smoking 
status
MAF 
(MAC)†
OR (95% CI) p value Association with COPD‡ Eﬀ ect on FEV1
OR (95% CI) p value Beta (SE)§ p value
Extremes of FEV1: low vs high FEV1
Genome-wide signiﬁ cant in 
heavy smokers
Chr12:114743533 RBM19/TBX5 T/C (T) 0·737 Never 0·002
(60)
0·97
(0·57–1·67)
0·90 1·16
(0·54–2·51)
0·71 0·101 
(0·118)
0·39
·· ·· ·· ·· Heavy 0·001
(39)
11·73
(5·03–27·32)
1·16 × 10–⁸ 6·44
(2·89–14·37)
5·40 × 10–⁶ –0·728
(0·151)
1·31 × 10–⁶
Genome-wide signiﬁ cant in 
never smokers
rs34712979 ¶||, 
Chr4:106819053
NPNT G/A (A) 1·000 Never 0·268
(7842)
1·27
(1·20–1·34)
9·62 × 10–¹⁶ 1·36
(1·27–1·46)
2·10 × 10–¹⁸ –0·087
(0·010)
2·27 × 10–¹⁷
·· ·· ·· ·· Heavy 0·261
(7636)
1·18
(1·11–1·25)
1·10 × 10–⁸ 1·26
(1·18–1·34)
5·43 × 10–¹³ –0·056
(0·010)
4·22 × 10–⁸
rs9274600¶, Chr6:32635592 HLA-DQB1/
HLA-DQA2
A/G (G) 0·962 Never 0·472
(13 838)
1·18
(1·13–1·25)
1·26 × 10–¹⁰ 1·24
(1·16–1·32)
1·95 × 10–¹¹ –0·057
(0·009)
6·72 × 10–¹⁰
·· ·· ·· ·· Heavy 0·468
(13 719)
1·05
(1·00–1·10)
0·096 1·08
(1·02–1·14)
8·58 × 10–³ –0·019
(0·009)
0·037
rs2532349, Chr17:44339473 KANSL1 A/G (G) 0·976 Never 0·242
(7088)
1·22
(1·15–1·29)
1·66 × 10–¹⁰ 1·24
(1·16–1·34)
3·97 × 10–⁹ –0·063
(0·011)
3·22 × 10–⁹
·· ·· ·· ·· Heavy 0·233
(6832)
1·15
(1·08–1·21)
1·47 × 10–⁵ 1·14
(1·07–1·22)
9·56 × 10–⁵ –0·050
(0·011)
3·64 × 10–⁶
rs7218675, Chr17:73513185 TSEN54 C/A (C) 0·997 Never 0·291
(8538)
1·18
(1·11–1·25)
1·18 × 10–⁸ 1·22
(1·14–1·31)
4·56 × 10–⁹ –0·052
(0·010)
1·94 × 10–⁷
·· ·· ·· ·· Heavy 0·290
(8503)
1·04
(0·98–1·09)
0·23 1·06
(1·00–1·13)
0·059 –0·017
(0·010)
0·080
rs2047409, Chr4:106137033 TET2 G/A (G) 0·998 Never 0·345
(10 117)
1·17
(1·11–1·23)
1·31 × 10–⁸ 1·17
(1·10–1·25)
1·64 × 10–⁶ –0·056
(0·009)
4·19 × 10–⁹
·· ·· ·· ·· Heavy 0·356
(10 440)
1·07
(1·02–1·13)
8·01 × 10–³ 1·09
(1·03–1·16)
2·92 × 10–³ –0·023
(0·009)
0·014
Smoking behaviour: heavy vs never smokers
rs4466874, Chr11:112861434 NCAM1 T/C (C) 0·998 NA 0·385
(37 709)
1·10
(1·07–1·13)
3·22 × 10–¹² NA NA NA NA
rs10193706, Chr2:146316319 TEX41/ 
PABPC1P2
A/C (A) 0·983 NA 0·473
(46 280)
1·09
(1·06–1·12)
1·10 × 10–¹⁰ NA NA NA NA
rs143125561; rs57342388, 
Chr20:31162590
NOL4L C/CACGG 
(CACGG)
0·983 NA 0·233
(22 820)
1·10
(1·07–1·13)
4·65 × 10–⁹ NA NA NA NA
rs61784651||, Chr1:99445471 LPPR5 C/T (T) 1·000 NA 0·170
(16 609)
1·10
(1·07–1·14)
2·89 × 10–⁸ NA NA NA NA
rs10807199, Chr6:38901867 DNAH8 C/T (T) 1·000 NA 0·473
(46 286)
1·08
(1·05–1·11)
3·17 × 10–⁸ NA NA NA NA
For variants that showed association with extremes of FEV1 in either heavy smokers or never smokers, the results from both the never smokers and heavy smokers are presented. p values and 95% CIs for signals 
of association with extremes of FEV1 are genomic control corrected for the result in the smoking status stratum for which the signal was most highly signiﬁ cant, and uncorrected for the alternate smoking status 
stratum. All smoking behaviour results are genomic control corrected. Genomic control λs are given in the appendix (pp 113–116). For variants that had genome-wide signiﬁ cant evidence of association for 
smoking behaviour (and not for extremes of FEV1), association with COPD and eﬀ ect on FEV1 were not assessed. Chromosome and position relate to National Center for Biotechnology Information build 37 
(hg19). ··=as above. COPD=chronic obstructive pulmonary disease. FEV1=forced expiratory volume in 1 s. MAC=minor allele count. MAF=minor allele frequency. NA=not applicable. OR=odds ratio. SE=standard 
error. *Indication of certainty of imputation for this variant; an imputation info score of 1 suggests a variant imputed with the highest certainty or a directly genotyped variant. †In samples included in the 
comparison. ‡Analysis of Global Initiative for Chronic Obstructive Lung Disease stage 2+ COPD cases versus controls (heavy smokers: 5803 cases vs 4661 controls; never smokers: 3761 cases vs 4792 controls). 
§Eﬀ ect on FEV1 beta values are eﬀ ect-size estimates on an inverse-normal transformed scale after adjustments for age, age², sex, height, and ancestry principal components (appendix p 21). ¶Novel signals of 
association within previously reported loci. ||Directly genotyped. 
Table 2: Novel genome-wide signiﬁ cant signals of association with extremes of forced expiratory volume in 1 s or smoking behaviour
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spanned INTS12, GSTCD, and NPNT (appendix p 102). 
The second (rs2047409) was 552 kb from the signals at 
INTS12, GSTCD, and NPNT and was localised to TET2. 
The signal of association for rs34712979 was strongest in 
never smokers (p=9·62 × 10–¹⁶; table 2) and was weakly 
correlated (linkage disequilibrium r²=0·31) with another 
SNP in NPNT—rs6856422—which has also been 
identiﬁ ed as a novel secondary signal of association at 4q24 
by an independent concurrent study of lung function in 
the general population.35 When rs6856422 was included as 
Figure 3: Manhattan plots for low versus high forced expiratory volume in 1 s in never smokers and heavy smokers and for heavy versus never smokers
p values are from a Score test and have genomic control applied unless the MAC was less than 400 and Score test p<1·00 × 10–⁶, in which case p values are from a Firth 
test with no genomic control. Novel loci are underlined and novel signals at previously reported loci are shown in bold. The dashed red line shows the threshold for 
genome-wide signiﬁ cance (p<5 × 10–⁸). Variants with suggestive evidence of association (p<5 × 10–⁷) are coloured red. Quantile–quantile plots for these analyses are 
shown in the appendix (pp 113–116). FEV1=forced expiratory volume in 1 s. MAC=minor allele count. 
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a covariate in our analysis, the signal for rs34712979 
(p=9·62 × 10–¹⁶) was only slightly attenuated (p=4·66 × 10–¹¹). 
The novel signal at TET2 (rs2047409) also showed strongest 
association in never smokers (p=1·31 × 10–⁸). rs2047409 is 
separated from the previously reported association of 
rs10516526 with FEV1 (GSTCD)5,7 by a recombination 
hotspot and is statistically independent (rs105165267 
included as a covariate; rs2047409, p=9·8 × 10–⁹). TET2 
encodes tet methylcytosine dioxygenase 2, which has a role 
in myelopoiesis, and SNPs in TET2 have shown association 
with height.36 TET2 was diﬀ erentially expressed during 
fetal lung development (appendix pp 58–59).
We detected a signal of association with FEV1 extremes 
within the HLA region on chromosome 6 that was 
correlated with a previously reported signal of association 
with asthma.37 The signal we report was strongest in 
never smokers (rs9274600, p=1·26 × 10–¹⁰; table 2; 
appendix p 102). With an imputed proxy (rs17843604) of 
the asthma-associated SNP rs927334937—included as a 
covariate in the analysis of rs9274600—the signal for 
rs9274600 was attenuated (p=5·66 × 10–⁴), conﬁ rming 
that rs9274600 and rs9273359 are correlated. After 
exclusion of individuals with doctor-diagnosed asthma, 
the odds ratio for rs9274600 decreased from 1·18 (95% CI 
1·11–1·25) to 1·14 (1·08–1·20), but remained signiﬁ cant 
(p=3·25 × 10–⁶; appendix p 103). This signal is 
independent of nearby signals reported for lung 
function,5,7,8 including rs7764819,38 which is 45 kb from 
rs9274600 (association for rs9274600 conditioned on 
rs7764819; p=6·71 × 10–¹¹).
We identiﬁ ed a rare SNP that was associated with FEV1 
extremes in heavy smokers only, after adjusting for 
pack-years of smoking (p=1·16 × 10–⁸; table 2). This 
intergenic SNP on chromosome 12 (chr12:114743533, 
MAF=0·13%) also showed weak evidence of association 
with smoking behaviour (p=6·12 × 10–³; appendix 
pp 60–62). We noted evidence for change in expression 
levels with increasing fetal lung age (p=0·04) for one or 
more probes after adjustment for multiple testing for the 
nearby gene TBX5 (appendix pp 58–59).
We noted a broad signal of association (~1·5 Mb) in an 
inversion locus at 17q21.31 (rs2532349, near KANSL1; 
appendix p 97). This signal was strongest in never 
smokers (rs2532349, p=1·66 × 10–¹⁰), but was also detected 
in heavy smokers (p=1·47 × 10–⁵). Genes in this locus, 
which include MAPT and CRHR1, have previously been 
associated with pulmonary ﬁ brosis39,40 and inhaled 
corticosteroid response in asthma.41 SNP rs2532349 (and 
SNPs in strong linkage disequilibrium [r²>0·8]) was 
associated with mRNA expression levels of at least 
15 genes in lung and blood (appendix pp 63–70). We 
identiﬁ ed diﬀ erential expression for six genes at 17q21.31 
during fetal lung development (and for four genes on 
diﬀ erent chromosomes regulated by trans eQTLs at 
17q21.41; appendix pp 58–59). Relatively abundant novel 
transcripts (ie, compared with other transcripts detected) 
were identiﬁ ed by RNA sequencing in human bronchial 
epithelial cells for WNT3 and LRRC37A4P; expression of 
both genes was associated with rs2532349 in lung and 
blood (appendix pp 104–109). The SNP rs2532349 
(MAF=24%) was in linkage disequilibrium with the 
inversion (r²>0.9); the allele associated with low FEV1 was 
positively correlated with the inverted haplotype.42,43 The 
inversion locus contains structural variation resulting 
from three duplication events (150–300 kb).42,43 We 
imputed the nine common structural haplotypes 
(appendix pp 23–24)42 and found that the number of 
copies of the 150 kb region containing the 5ʹ end of 
KANSL1 (the entire 150 kb duplication region found only 
in individuals who carry the inversion and a nested 
region of the 300 kb duplication region found only in 
individuals who do not carry the inversion) was associated 
with extremes of FEV1 (p=2·40 × 10–⁶; appendix p 71). The 
sentinel SNP rs2532349 lies within this region.
A second signal of association with FEV1 extremes on 
chromosome 17 (17q25.1) was within TSEN54 and occurred 
only in never smokers (rs7218675; p=1·18 × 10–⁸; table 2). 
TSEN54 encodes a subunit of the tRNA splicing 
endonuclease complex, and rs7218675 was associated with 
expression of KIAA0195, TSEN54, and GRB2 in blood and 
expression of GRB2 in lung tissue (appendix pp 63–66). 
GRB2 is a ligand of the epidermal growth factor receptor, 
which links signalling by epidermal growth factor with 
the MAPK/ERK signalling pathway, triggering cell 
proliferation. RNA sequencing in human bronchial 
epithelial cells identiﬁ ed a relatively abundant novel fusion 
transcript of TSEN54 and LLGL2 (appendix p 108). 
To corroborate the new signals we identiﬁ ed in TET2 
and TSEN54, we present evidence of association with FEV1 
in a previously reported study8 of 48 201 individuals 
(p=9·9× 10–⁵ and p=0·006, respectively; appendix pp 24, 82).
We identiﬁ ed a further 21 loci with suggestive 
(5 × 10–⁸<p<5 × 10–⁷) evidence of association with FEV1 
extremes (appendix pp 72–73), including six rare variants 
with a minor allele count less than 400. These included 
signals in CCDC91 and RSRC1, both of which showed 
genome-wide signiﬁ cant association with lung function 
in an independent concurrent study of lung function in 
the general population.35
By comparing heavy smokers and never smokers, we 
identiﬁ ed ﬁ ve novel regions of association with smoking 
behaviour and conﬁ rmed four previously reported loci 
(15q25, 7p14, DBH, and BDNF; table 2; appendix 
pp 32–37).17–19 The novel signals included rs4466874, in an 
intron of NCAM1 (chromosome 11), and rs10193706, an 
intergenic SNP on chromosome 2 downstream of TEX41 
and upstream of PABPC1P2 (table 2; appendix 
pp 110–112). Uncorrelated (r²<0·0001 with rs4466874) 
SNPs in TTC12 and ANKK1, near to NCAM1, have also 
previously shown association with nicotine dependence 
(appendix pp 74–75).44 A proxy of rs10193706 on 
chromosome 2 (rs953246, r²=0·48) is a trans eQTL for 
NCAM1 on chromosome 11 in brain tissue (appendix pp 
76–77). Another proxy of rs10193706 on chromosome 2 
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(rs12622738, r²=0·86) is a trans eQTL in the substantia 
nigra for WDR61 on chromosome 15, 300 kb from the 
established 15q25 smoking locus (appendix pp 76–77).
We also noted novel genome-wide signiﬁ cant signals of 
association with smoking behaviour in NOL4L, LPPR5, 
and DNAH8 (table 2, appendix pp 110–112). A SNP in 
C20orf203, near to NOL4L, but independent of our 
sentinel variant, has previously been implicated in 
nicotine dependence.45 We identiﬁ ed secondary 
independent signals, which did not reach genome-wide 
signiﬁ cance, at three of the loci associated with smoking 
behaviour (appendix pp 56–57, 99–101),46 including a 
novel rare (MAF=0·09%) intergenic SNP near NCAM1. 
For novel signals for smoking behaviour, we did a meta-
analysis of summary statistics from two previous, less 
powerful studies17,19 and found corroborative evidence for 
NCAM1, TEX41/PABPC1P2, and NOL4L (eg, for smoking 
initiation p=0·0003, p=0·017, and p=0·0006, respectively; 
appendix pp 24, 83–84). We identiﬁ ed a further eight 
loci with suggestive (5 × 10–⁸<p<5 × 10–⁷) evidence of 
association with smoking behaviour (appendix p 72–73), 
including CHRNA4 at 20q13.33 (p=1·01 × 10–⁷).47
In a genome-wide gene–smoking interaction analysis, 
although common SNPs on chromosomes 6 and 19 
showed suggestive SNP–smoking interactions (p<5 × 10–⁷; 
appendix p 78), no gene–smoking interactions were 
detected at genome-wide signiﬁ cance (p<5 × 10–⁸). Three 
of the six variants associated with FEV1 extremes (table 2) 
showed weak evidence of interaction with smoking 
(Bonferroni correction for six tests p=0·0083; appendix 
pp 60–62), including common variants at the HLA-
DQB1/HLA-DQA2 and TSEN54 loci and the rare variant 
at the RBM19/TBX5 locus. In a meta-analysis of the 
genome-wide association test statistics for low FEV1 
versus high FEV1 across heavy and never smokers, 
motivated by our ﬁ nding of shared genetic causes 
between heavy and never smokers and to increase the 
sample size, we identiﬁ ed an additional six novel 
genome-wide signiﬁ cant signals of association with FEV1 
extremes. These included CCDC91, reported as a novel 
signal of association with lung function in the general 
population by a concurrent study,35 and SLMAP, for 
which there is corroborative evidence of association with 
lung function (appendix pp 79–80).8 Our pathway analysis 
identiﬁ ed a novel signal of enrichment of the histone 
subset of the chromatin packaging and remodelling 
process gene set, which was independently replicated in 
a concurrent GWAS of lung function in the general 
population (appendix p 81).35 Replication of a previously 
reported8 enrichment of the systemic lupus 
erythematosus pathway was also noted (appendix p 81).
Discussion
We describe, to our knowledge, the ﬁ rst genetic 
association analyses in UK Biobank, targeting the genetic 
architecture of smoking behaviour and lung function 
phenotypes. By sampling from the extremes of the FEV1 
and smoking phenotype distributions, we identiﬁ ed 
novel associations for FEV1 and smoking behaviour. We 
show genome-wide evidence for shared genetic causes of 
low FEV1 between heavy smokers and never smokers. 
Furthermore, our analyses suggest that smoking is only 
likely to interact with a small proportion of the genetic 
eﬀ ects we have identiﬁ ed on lung function—that is, 
smoking and genetic eﬀ ects generally act separately. We 
also show shared genetic causes of airﬂ ow obstruction 
between participants who reported doctor-diagnosed 
asthma and those who did not.
Two of our novel signals of association with smoking 
behaviour implicate NCAM1; one SNP lies within an 
intron of NCAM1 and a second variant, located distantly 
on chromosome 2, is a trans eQTL for NCAM1 in brain 
tissue (medulla)—ie, it is associated with the level of 
expression of NCAM1. This second SNP is also a trans 
eQTL in substantia nigra tissue for another gene called 
WDR61, which is close to the genes CHRNA3 and 
CHRNA5 at 15q25—a locus strongly associated with 
smoking behaviour.17–19 The substantia nigra plays an 
important part in reward and addiction,48 but little is 
known about WDR61 other than that expression can be 
induced by mechanical strain in mesenchymal stem 
cells.49
We describe six new signals of association with FEV1 
extremes, all of which were also associated with COPD 
using our deﬁ nition based on spirometry. Five of these 
signals were most strongly associated with extremes of 
FEV1 (low vs high) in never smokers. The signal at 
17q21.31 for extremes of FEV1 suggests a role for 
structural variation and epigenetic regulation in lung 
health. We found that the number of copies of the 5ʹ end 
of KANSL1—a gene disrupted by duplication events—is 
associated with FEV1 extremes. KANSL1 encodes a 
protein that is a key component of the NSL1 (histone 
acetyltransferase) complex.50 The disruption of the gene 
gives rise to a novel truncated transcript,42 which encodes 
a protein missing a domain essential for key interactions 
with other proteins important for NSL1 function.51 
Therefore, widespread eﬀ ects on gene regulation 
through altered histone acetylation could underlie this 
association. Reduced expression of KANSL1 causes a 
rare multisystem disorder,52,53 suggesting an essential 
role for KANSL1 in epigenetic regulation. In a genome-
wide pathway analysis, we identiﬁ ed the histone gene 
set, further implicating a role for epigenetic regulation 
in lung health.
We maximised the power of our study by sampling 
from the extremes of a large biobank. No other similar 
resources of a comparable size were available for 
replication studies. Nevertheless, the novel genome-wide 
signiﬁ cant signals of association with FEV1 extremes in 
NPNT and KANSL1 in never smokers were also 
signiﬁ cantly associated in the independent set of heavy 
smokers. Furthermore, to corroborate the new signals we 
identiﬁ ed in TET2 and TSEN54, we present evidence of 
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association with FEV1 in a previously reported large study 
of FEV1 in the general population.8 However, the rare 
SNP on chromosome 12 for which we found association 
with extremes of FEV1 was exclusive to the recently 
released UK10K Project component of the imputation 
panel and has not yet been measured in suitably large 
studies. Our comparison of smokers and never smokers 
represents a powerful approach because of the restriction 
to heavy smokers rather than ever smokers. For novel 
signals for smoking behaviour, we present additional 
evidence of association with smoking behaviour for 
NCAM1, TEX41/PABPC1P2, and NOL4L in independent 
populations.17,19 Although these independent datasets 
have limited power, they provide corroboration of key 
genome-wide signiﬁ cant ﬁ ndings in UK BiLEVE.
One of the strengths of our study design was that the 
genotyping platform we used allowed for ﬁ ne mapping 
of regions already known to contain genetic variants that 
aﬀ ect lung function. For example, we were able to 
identify a novel signal in NPNT that was independent of 
the previously reported signal of association at this 
locus (spanning GSTCD, INTS12, and NPNT). The 
independent NPNT signal captured by the genotyped 
variant rs34712979 was not detected in previous or 
concurrent studies because it was neither directly 
genotyped nor imputed with suﬃ  cient quality; this 
ﬁ nding highlights a further advantage of the UK BiLEVE 
and UK Biobank array design.
The design of this genotyping array combined the best 
features of existing genome-wide platforms targeting 
common SNPs (MAF ≥5%) and putative functional 
exome chip content, plus additional content to improve 
imputation of low-frequency variants (MAF 1–5%). In 
combination with a new large UK-speciﬁ c imputation 
reference panel (UK10K Project), these features increase 
the potential to discover novel signals. In our study, more 
than 28·5 million variants were imputed; current large 
meta-analyses combining data from several studies with 
older arrays and using equivalent quality control ﬁ lters 
after imputing to 1000 Genomes Project Phase 1 alone 
typically measure about 10·6 million variants.35 The 
genome-wide genotype data for these 50 008 individuals 
have been deposited in UK Biobank to be made available 
to other approved research projects across many disease 
areas. The UK BiLEVE array was used as a prototype for 
the array that is being used in the remaining roughly 
450 000 UK Biobank participants. The UK Biobank array 
shares more than 95% of its content with the UK BiLEVE 
array. When genotyping of all UK Biobank participants is 
complete, UK Biobank will provide a unique resource for 
genome-wide studies of quantitative traits, nested case-
control studies, and studies in which longitudinal 
outcomes can be studied.
Despite the strengths of using a large resource such as 
UK Biobank, this study has some limitations. In 
particular, there is a trade-oﬀ  between obtaining the large 
sample sizes generally needed for genetic studies and the 
depth of phenotyping that is practicable in such large 
populations. Our spirometric deﬁ nition of COPD was 
not based on bronchodilator reversibility testing, 
although we have shown previously that by limiting 
inclusion to individuals with GOLD stage 2+ spirometry, 
most of these individuals are likely to have COPD 
according to more rigorous criteria.13 Similarly, our 
deﬁ nition of asthma was based on self-reporting of 
doctor-diagnosed disease. These limitations might have 
reduced our ability to identify some novel disease 
associations, although we were able to replicate many 
known associations using this approach.
In summary, we show the usefulness in sampling from 
the extremes of UK Biobank data to identify novel genetic 
signatures underlying phenotypes important in the 
development of airway disease and smoking behaviour. 
The ongoing genotyping, and further phenotyping, of 
the rest of the UK Biobank resource will facilitate 
further GWAS, which will undoubtedly improve our 
understanding of the genetic and molecular basis of 
common disease.
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